middle.news
PYC Therapeutics Launches Global Repeat Dose Trial for Vision-Restoring Drug
9:25am on Tuesday 21st of October, 2025 AEDT
•
Biotechnology
Read Story
PYC Therapeutics Launches Global Repeat Dose Trial for Vision-Restoring Drug
9:25am on Tuesday 21st of October, 2025 AEDT
Key Points
Initiation of global Phase 1b repeat dose MYRTLE study for PYC-001
Targeting Autosomal Dominant Optic Atrophy (ADOA), a rare blinding disease
Study to evaluate safety, tolerability, and efficacy across multiple dosing regimens
Data anticipated in H2 2026 to establish clinical proof of concept
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Pyc Therapeutics (ASX:PYC)
OPEN ARTICLE